# Empagliflozin to Prevent Post-Operative Atrial Fibrillation

Study · id `cardio:ct-nct06124937` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06124937](<https://clinicaltrials.gov/study/NCT06124937>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06124937

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 492 participants.

## Technical summary

Registry record NCT06124937. Randomized; quadruple masking; primary purpose prevention. Start 2023-11-07 (actual); primary completion 2024-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 492 participants (planned count; ClinicalTrials.gov record NCT06124937, source copy `cardio:ctgov-nct06124937-2023-11-22`, retrieved 2026-10-26)
- Started: 2023-11-07 (actual) (ClinicalTrials.gov record NCT06124937, source copy `cardio:ctgov-nct06124937-2023-11-22`, retrieved 2026-10-26)
- Primary completion: 2024-12-30 (anticipated) (ClinicalTrials.gov record NCT06124937, source copy `cardio:ctgov-nct06124937-2023-11-22`, retrieved 2026-10-26)
- Completion: 2024-12-30 (anticipated) (ClinicalTrials.gov record NCT06124937, source copy `cardio:ctgov-nct06124937-2023-11-22`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT06124937, source copy `cardio:ctgov-nct06124937-2023-11-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06124937-2023-11-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin to Prevent Post-Operative Atrial Fibrillation
- Acronym: EMPOAF
- Condition: Post-operative Atrial Fibrillation
- Condition: CABG
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: Rajaie Cardiovascular Medical and Research Center
- Lead sponsor class: OTHER
- Collaborator: Tehran Heart Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Rajaie Cardiovascular Medical and Research Center (`cardio:org-rajaie-cardiovascular-medical-and-research-center`)

## Provenance

Content hash: 48b16191b64244c3b4cb6b41a2f2e456decdd83169ebbc6522d6c2bebe7819c2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
